SCHEMBL26096928

SCHEMBL26096928

Cc1cccc2cc(C(=O)NCc3ccccc3Cl)[nH]c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 2/20 0.57
POLB P06746 1/20 0.53
KMT2A Q03164 2/20 0.50
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
LMNA P02545 4/20 0.49
ALDH1A1 P00352 2/20 0.49
HTT P42858 2/20 0.49
TP53 P04637 2/20 0.49
PKM P14618 1/20 0.49
MAPK1 P28482 1/20 0.49
SMYD3 Q9H7B4 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SETD2 Q9BYW2 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26099053 0.84 NSD2 (0.55) NSD2HDAC3HDAC1ALDH1A1SMYD3
SCHEMBL6656620 0.81 POLB (0.59) POLBHDAC3HDAC1ALDH1A1TP53
SCHEMBL25037872 0.80 NSD2 (0.51) NSD2HDAC3HDAC1LMNATP53
SCHEMBL25040570 0.79 NSD2 (0.50) NSD2HDAC3HDAC1LMNATP53
SCHEMBL26097800 0.79 HRH4 (0.55) NSD2HDAC3HDAC1LMNATP53
SCHEMBL25037901 0.79 HRH4 (0.55) NSD2HDAC3HDAC1LMNATP53
SCHEMBL26098269 0.78 NSD2 (0.51) NSD2POLBHDAC3HDAC1LMNA
SCHEMBL25039938 0.78 SETD2 (0.60) NSD2HDAC3HDAC1LMNAALDH1A1
SCHEMBL25040346 0.78 SMYD3 (0.48) NSD2HDAC3HDAC1LMNATP53
SCHEMBL26097294 0.78 NSD2 (0.56) NSD2HDAC3HDAC1SMYD3SETD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240299352-A1 COMBINATION THERAPIES WITH SETD2 INHIBITORS Epizyme, Inc. 2024-09-12 US disclosed
US-20230133671-A1 SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES Epizyme, Inc. (US) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240299352-A1 COMBINATION THERAPIES WITH SETD2 INHIBITORS SETD2, CARM1, SETDB1 NSD2 35/4885POLB 224/4885KMT2A 24/4885
US-20230133671-A1 SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES EZH2, HDAC2, SETD2 NSD2 14/4885POLB 2014/4885KMT2A 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.